Scribe Therapeutics co-founders David Savage and Benjamin Oakes sat down for an Office Hours session to break down groundbreaking research on base editing precision and safety in genetic medicines.
Public source
Publisher name
Public post
๐ง๐ต๐ถ๐ ๐ถ๐ ๐๐ต๐ ๐'๐บ ๐ฝ๐ฟ๐ผ๐๐ฑ ๐๐ผ ๐๐ผ๐ฟ๐ธ ๐ฎ๐ ๐ฆ๐ฐ๐ฟ๐ถ๐ฏ๐ฒ. Our co-founders, David Savage and Benjamin Oakes, just sat down for Office Hours to break down groโฆ
Company
Scribe Therapeutics
CRISPR by Designโข
- Industry
- Biotechnology Research
- Location
- Alameda, US
- Company size
- 51โ200 employees
About Scribe Therapeutics
Scribe Therapeutics is pioneering highly engineered CRISPR technologies designed to reshape the treatment of disease by enabling earlier intervention, improved outcomes, and longer, healthier lives.
See moreLatest activity
Latest activity from Scribe Therapeutics
9 signals
People
Scribe Therapeutics is hiring a Director of Investor Relations to lead Scribe's growth as a public company through education and communication.
Research & Knowledge
Scribe Therapeutics received awards from the California Institute for Regenerative Medicine (CIRM) totaling more than $25 million to advance its gene editing programs STX-1200 for Lp(a) lowering and STX-1400 for triglyceride lowering toward clinical entry.
Research & Knowledge
Scribe Therapeutics published a manuscript on ELXR, its highly engineered epigenetic silencing technology.
Discover more
Similar signals
Similar public activity from other companies.
Presence & Recognition
Editas Medicine
Editas Medicine is participating in a fireside chat at the Wells Fargo Healthcare Conference on Tuesday at 4:30 p.m. ET.
Presence & Recognition
EditCo Bio
EditCo Bio and Promega Corporation hosted the Drafts & Discoveries event at Timber + Tide in South San Francisco on October 8, 2026, featuring scientific talks, open discussion, and networking across cell engineering, protein degradation, and next-generation drug discovery.
Presence & Recognition
Touchlight
Touchlight featured two leading experts in The Great DNA Debate: Plasmid vs. Cell-Free DNA to unpack real-world data, practical use cases, and fresh perspectives on genetic medicine.
Presence & Recognition
Curi Bio
Curi Bio is presenting AAV capsid screening data at a webinar with Dyno Therapeutics on Wednesday, September 23 at 8 AM PT.
Presence & Recognition
PacBio